
The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about HGSI.DL.
Find the members with the highest scoring picks in HGSI.DL.
See what the Wall Street professionals think, according to their public statements and filings.